MX337999B - Derivados de 8-hidroxiquinolina. - Google Patents

Derivados de 8-hidroxiquinolina.

Info

Publication number
MX337999B
MX337999B MX2012012883A MX2012012883A MX337999B MX 337999 B MX337999 B MX 337999B MX 2012012883 A MX2012012883 A MX 2012012883A MX 2012012883 A MX2012012883 A MX 2012012883A MX 337999 B MX337999 B MX 337999B
Authority
MX
Mexico
Prior art keywords
group
groups
lower alkyl
optionally substituted
hydrogen atom
Prior art date
Application number
MX2012012883A
Other languages
English (en)
Other versions
MX2012012883A (es
Inventor
Puskás László
Kanizsai Iván
Gyuris Márió
Ozsvári Béla
Fehér Liliána
Tamás Gábor
Szabó Csaba
Madácsi Ramóna
Original Assignee
Avidin Kutató Fejlesztó És Kereskedelmi Korlátolt Felelósségü Társaság
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avidin Kutató Fejlesztó És Kereskedelmi Korlátolt Felelósségü Társaság filed Critical Avidin Kutató Fejlesztó És Kereskedelmi Korlátolt Felelósségü Társaság
Publication of MX2012012883A publication Critical patent/MX2012012883A/es
Publication of MX337999B publication Critical patent/MX337999B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

(ver fórmula (I)) La invención se relaciona con compuestos de la fórmula general (I) y sus sales farmacéuticamente aceptables (fórmula en la cual R1 representa un átomo de hidrógeno, un grupo alquilo inferior, un grupo alquenilo inferior, un grupo cicloalquilo inferior, un grupo arilo, un grupo aralquilo o un grupo heterocíclico, en donde los grupos anteriores están opcionalmente sustituidos en posición orto, meta y/o para con 1, 2, 3 ó 4 grupos que retiran electrones o grupos donadores de electrones; R2 representa un átomo de hidrógeno, un grupo alquilo inferior, un grupo arilo, un grupo aralquilo o un grupo heterocíclico en donde los grupos anteriores están opcionalmente sustituidos con uno o más átomos de halógeno; R3 representa un grupo alquilo inferior, un grupo arilo, un grupo aralquilo o un grupo heterocíclico, en donde los grupos anteriores están opcionalmente sustituidos en posición orto, meta o para con 1, 2, 3 ó 4 grupos que retiran electrones o grupos que donan electrones; R4 representa un átomo de hidrógeno, un grupo alquilo inferior o cualquier grupo con funcionalidad ácida; n es 1 ó 2). Los compuestos de acuerdo con la invención se pueden utilizar en la medicina principalmente para el tratamiento de enfermedades asociadas con estrés neurológico y/u oxidativo.
MX2012012883A 2010-05-06 2011-05-06 Derivados de 8-hidroxiquinolina. MX337999B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1000243A HUP1000243A2 (en) 2010-05-06 2010-05-06 8-hidroxy-quinoline derivatives
PCT/HU2011/000043 WO2011148208A1 (en) 2010-05-06 2011-05-06 8-hydroxy-quinoline derivatives

Publications (2)

Publication Number Publication Date
MX2012012883A MX2012012883A (es) 2013-03-20
MX337999B true MX337999B (es) 2016-03-30

Family

ID=89989711

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012012883A MX337999B (es) 2010-05-06 2011-05-06 Derivados de 8-hidroxiquinolina.

Country Status (20)

Country Link
US (1) US8871937B2 (es)
EP (1) EP2566849B1 (es)
JP (1) JP5812541B2 (es)
KR (1) KR101837974B1 (es)
CN (1) CN102985407B (es)
AU (1) AU2011256989B2 (es)
CA (1) CA2798419C (es)
CY (1) CY1122426T1 (es)
DK (1) DK2566849T3 (es)
EA (1) EA021026B1 (es)
ES (1) ES2761832T3 (es)
HR (1) HRP20192278T1 (es)
HU (2) HUP1000243A2 (es)
MX (1) MX337999B (es)
NZ (1) NZ603967A (es)
PL (1) PL2566849T3 (es)
PT (1) PT2566849T (es)
RS (1) RS59678B1 (es)
SI (1) SI2566849T1 (es)
WO (1) WO2011148208A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP1500098A2 (hu) 2015-03-09 2016-09-28 Avidin Kft 8-hidroxikinolin származékok új enantiomerjei és szintézisük
WO2017066245A1 (en) * 2015-10-12 2017-04-20 Health Research, Inc. Methods for inducing apoptosis in cancer cells
CN105367553A (zh) * 2015-12-04 2016-03-02 广东工业大学 一种他克林-8-羟（胺）基喹啉衍生物及其应用
HUP1600234A2 (en) 2016-04-05 2017-12-28 Mta Termeszettudomanyi Kutatokoezpont Mdr-reversing 8-hydroxy-quinoline derivatives

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544972B1 (en) 1997-09-25 2003-04-08 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
CA2319131A1 (en) 1998-01-26 1999-07-29 Walter H. Moos Mitochondria protecting agents for treating mitochondria associated diseases
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
JP2003508379A (ja) 1999-08-27 2003-03-04 サイトビア インコーポレイテッド 置換α−ヒドロキシ酸カスパーゼインヒビターおよびその使用
US6890896B1 (en) 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
GB0011095D0 (en) 2000-05-08 2000-06-28 Black James Foundation astrin and cholecystokinin receptor ligands (III)
US6521617B2 (en) 2000-10-13 2003-02-18 The Johns Hopkins University Treatment of apoptotic cell death
WO2002048092A2 (en) 2000-12-15 2002-06-20 Mitokor Compounds for altering mitochondrial function and cellular responses
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
ZA200508985B (en) 2001-07-10 2006-07-26 Biogen Idec Inc Inhibition of apotosis process and improvement of cell performance
DE10144153A1 (de) 2001-09-07 2003-03-27 Newfrey Llc Halteclip mit versetzten Rastfingern
WO2003072024A2 (en) 2002-02-13 2003-09-04 Beth Israel Deaconess Medical Center, Inc. Methods of treating vascular disease
JP2007501857A (ja) 2003-02-28 2007-02-01 イノテック ファーマシューティカルズ コーポレーション 四環系ベンズアミド誘導体およびその使用方法
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
CA2527420C (en) 2003-05-28 2013-01-08 Guilford Pharmaceuticals, Inc. Compounds, methods and pharmaceutical compositions for inhibiting parp
CA2971931C (en) 2004-01-23 2019-01-08 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
ATE461923T1 (de) 2005-11-15 2010-04-15 Abbott Lab Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
US7528174B2 (en) 2006-01-06 2009-05-05 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Selective targeting agents for mitochondria
CA2658793A1 (en) * 2006-07-25 2008-02-07 Daniel Dumas Quinoline derivatives
EP2139460A4 (en) * 2007-03-20 2011-09-07 Univ Brandeis COMPOSITIONS AND METHODS FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF AMYOTROPHER LATERAL SCLEROSIS AND ASSOCIATED NEUROLOGICAL DISEASES
US8183236B2 (en) * 2007-04-12 2012-05-22 University Of Southern California Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics
US20080293699A1 (en) 2007-05-25 2008-11-27 Burnham Institute For Medical Research Inhibitors of thapsigargin-induced cell death
US8138356B2 (en) * 2007-10-16 2012-03-20 Angiogeney, Inc. Chemical inhibitors of inhibitors of differentiation
US10301265B2 (en) * 2008-05-28 2019-05-28 Virginia I. Roxas-Duncan Small molecule inhibitors of botulinum neurotoxins
WO2011085126A2 (en) * 2010-01-06 2011-07-14 Errico Joseph P Methods and compositions of targeted drug development
US8658170B2 (en) * 2010-01-06 2014-02-25 Joseph P. Errico Combination therapy with MDM2 and EFGR inhibitors

Also Published As

Publication number Publication date
CY1122426T1 (el) 2021-01-27
HUP1000243A2 (en) 2012-01-30
EA201270787A1 (ru) 2013-04-30
EP2566849B1 (en) 2019-09-18
WO2011148208A1 (en) 2011-12-01
DK2566849T3 (da) 2020-01-02
CN102985407A (zh) 2013-03-20
HRP20192278T1 (hr) 2020-03-06
JP5812541B2 (ja) 2015-11-17
ES2761832T3 (es) 2020-05-21
CA2798419A1 (en) 2011-12-01
US20130131096A1 (en) 2013-05-23
JP2013525473A (ja) 2013-06-20
AU2011256989A1 (en) 2013-01-10
HUE050886T2 (hu) 2021-01-28
NZ603967A (en) 2014-06-27
EP2566849A1 (en) 2013-03-13
MX2012012883A (es) 2013-03-20
PL2566849T3 (pl) 2020-03-31
CN102985407B (zh) 2015-09-09
AU2011256989B2 (en) 2014-08-21
EA021026B1 (ru) 2015-03-31
US8871937B2 (en) 2014-10-28
PT2566849T (pt) 2020-01-06
KR101837974B1 (ko) 2018-03-13
CA2798419C (en) 2021-01-05
SI2566849T1 (sl) 2020-02-28
RS59678B1 (sr) 2020-01-31
KR20130029772A (ko) 2013-03-25
HU1000243D0 (en) 2010-06-28

Similar Documents

Publication Publication Date Title
UA109013C2 (en) INDOLISIN DERIVATIVES
TN2012000608A1 (en) Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
NZ601121A (en) 5-alkynyl-pyrimidines
MX2021008356A (es) Inhibidores de jak2 y alk2 y metodos para su uso.
MX2012015023A (es) Derivado novedoso de nicotinamida o sal del mismo.
AU2011274192A8 (en) Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof
CY1114520T1 (el) Παραγωγο ινδολιζινης και χρηση αυτου για ιατρικους σκοπους
ECSP12011622A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
CU20120099A7 (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
MX2016007056A (es) Metodos para preparar compuestos de benzoquinolina.
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
MX2012007582A (es) Compuestos de 4-fenoxi-nicotinamida o 4-fenoxi-pirimidina-5-carbox amida.
NZ603465A (en) Antimalarial drug which contains 5-aminolevulinic acid or derivative thereof as active ingredient
AR081893A1 (es) Derivados de acido 1-(2-fluorobifenil-4-il)-alquil carboxilico para la terapia de la amiloidosis transtiretina
PH12015502429A1 (en) Dicarboxylic acid compound
CY1122426T1 (el) Παραγωγα 8-υδροξυ-κινολινης
WO2014047232A3 (en) C-rel inhibitors and uses thereof
UA111950C2 (uk) Гетероциклічні сполуки для лікування або профілактики розладів, викликаних зниженою нейротрансмісією серотоніну, норепінефрину або допаміну
MX2015015485A (es) Derivado de glicinamida alfa-sustituida.
NZ608685A (en) Novel method of preparing benzoimidazole derivatives
MX2014005538A (es) 1-piridazinil-hidroxiimino-3-fenil-propanos como agonistas de proteina g-receptor acoplado a acido biliar 1 (gpbar1).
CY1118552T1 (el) Νεα παραγωγα πυριμιδινης ως αναστολεις φωσφοδιεστερασης 10 (pde-10)
IN2012DN06600A (es)
TN2011000530A1 (en) Thia-triaza-cyclopentazulenes as pi3-kinases inhibitors for the treatment of cancer
GEP201706680B (en) Catechol o-methyltransferase activity inhibiting compounds

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration